Scholars@Duke
Niharika Bansal Mettu

Niharika Bansal Mettu

Associate Professor of Medicine
Medicine, Medical Oncology
niharika.mettu@duke.edu
DUMC 3505, Durham, NC 27710
10 Bryan Searle Drive, Seeley G. Mudd Bldg, Room 433, Durham, NC 27710

Scholarly Works - Conferences

A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.

Conference Cancer Chemother Pharmacol · June 2019 PURPOSE: This study was conducted to define the maximum tolerated dose (MTD), recommended phase two dose (RPTD), and toxicities of gemcitabine + dasatinib (GD) and gemcitabine + dasatinib + cetuximab (GDC) in advanced solid tumor patients. METHODS: This st ... Full text Link to item Cite